In summary, circRNA-SFMBT2 is an important regulator of ERalpha signaling, and antagonizing circRNA-SFMBT2 expression may constitute a potential therapeutic strategy for breast cancer.
circRNA-SFMBT2 orchestrates ERalpha activation to drive tamoxifen resistance in breast cancer cells